# Alessa Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alessa-therapeutics

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: https://alessatherapeutics.com
- Total disclosed funding: $15M
- Latest round: Seed (Dec 12, 2024)
- Investors on record: 2

## About

Alessa Therapeutics, Inc., based in the US, focuses on developing innovative localized drug delivery systems for prostate cancer and benign prostate hyperplasia, enhancing treatment efficacy while reducing systemic exposure.Founded in 2018 in San Carlos, US, Alessa Therapeutics specializes in localized drug delivery for prostate-related conditions. The company has made two notable deals, with its most recent investment round occurring on December 12, 2024. Alessa Therapeutics raised USD 15.000 mn in a SEED round led by Mission BioCapital, with participation from Johnson & Johnson Innovation, bringing the total amount raised to USD 15.000 mn. The company was co-founded by Pamela Munster and Scott Thomas, with John Maroney serving as the current CEO.Alessa Therapeutics specializes in developing innovative localized drug delivery systems primarily targeting prostate cancer and benign prostate hyperplasia. The company’s core product offerings focus on implantable drug delivery systems designed to administer anti-androgen therapies directly to tumors in a sustained manner, minimizing systemic exposure and enhancing therapeutic efficacy. These systems aim to address critical needs in oncology, particularly for early-stage cancers, by providing a more tolerable and effective treatment alternative. The company is currently conducting clinical studies to validate the effectiveness of these technologies, engaging healthcare providers and oncologists as key customers in the United States and Australia, as well as potential markets in Europe and Asia. Alessa Therapeutics is committed to changing the treatment paradigm for prostate diseases, thereby improving outcomes for patients diagnosed with related conditions.Alessa Therapeutics generates revenue through partnerships and clinical trial funding, primarily in the biotechnology and pharmaceutical sectors. The company collaborates with research institutions and healthcare organizations to facilitate the development and clinical evaluation of its drug delivery systems. These partnerships often involve milestone payments and funding arrangements contingent upon the successful progress of clinical trials. While specific pricing structures are not disclosed, the revenue model is expected to include agreements for potential future commercialization of its flagship products, such as the Enolen® system for localized drug delivery in prostate cancer treatment. By focusing on strategic alliances and clinical collaborations, Alessa Therapeutics aims to secure funding that supports its innovative approach to cancer treatment and enhances its market presence.In December 2024, Alessa Therapeutics, Inc. raised USD 15.000 mn in seed funding led by Mission BioCapital, with participation from Johnson & Johnson Innovation. The company will utilize this funding to support its drug detection technology. Alessa Therapeutics is focusing on expanding its product offerings and plans to launch new products aimed at improving localized drug delivery systems for prostate cancer treatment. Additionally, the company is targeting expansion into European and Asian markets, with specific strategies being developed for these regions in the near future.

## Funding rounds

- Seed, Dec 12, 2024, $15M — Johnson & Johnson Innovation, Mission Biocapital

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Seed
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Seed